China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer that will allow the former to import and distribute Pfizer’s COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) in mainland China from December 14, 2022, to November 30, 2023. No financial details were disclosed.
Paxlovid: Indications and Market Approval
Paxlovid is used to treat adults with mild to moderate COVID-19 who have high risk factors for progression to severe diseases, such as the elderly (over 60 years old) or those with one or multiple risk factors such as chronic kidney disease, diabetes, cardiovascular disease, and chronic lung disease. A conditional market approval was awarded in China in February 2022. The price tag is RMB 2,300 (USD 330) per box, and the drug is included on the National Reimbursement Drug List (NRDL).
Manufacturing and Supply Agreements
Huahai Pharma entered into a manufacturing and supply agreement with Pfizer in August this year, under which the former will provide formulation contract production services in relation to Paxlovid in mainland China. The US major also entered into a five-year license and supply agreement with Ascletis Pharma Inc. (1672.HK) focused on the supply of ritonavir for use in Paxlovid in mainland China.-Fineline Info & Tech
